IMR Press / FBE / Volume 4 / Issue 1 / DOI: 10.2741/e363

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Recent advances on tea polyphenols

Show Less
1 The Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, Michigan, USA
2 Department of Chemistry, McGill University, Montreal, Quebec, H3a 2k6, Canada

*Author to whom correspondence should be addressed.

Academic Editor: Hala Gali-Muhtasib

Front. Biosci. (Elite Ed) 2012, 4(1), 111–131; https://doi.org/10.2741/e363
Published: 1 January 2012
(This article belongs to the Special Issue New emerging anticancer lead compounds from plants)
Abstract

Over the past decade many scientific and medical studies have focused on green tea for its long-purported health benefits. There is convincing evidence that tea is a cup of life. It has multiple preventive and therapeutic effects. This review thus focuses on the recent advances of tea polyphenols and their applications in the prevention and treatment of human cancers. Of the various polyphenols in tea, (-)-Epigallocatechin-3-gallate (EGCG) is the most abundant, and active compound studied in tea research. EGCG inhibits several molecular targets to inhibit cancer initiation and modulates several essential survival pathways to block cancer progression. Herein, we describe the various mechanisms of action of EGCG and also discuss previous and current ongoing clinical trials of EGCG and green tea polyphenols in different cancer types.

Keywords
EGCG
Proteasome
Cell Cycle Arrest
Apoptosis
Metastasis
NF-kappa B
AP-1
telomerase
COX-2
p53
VEGF
IGFR
Ras/MAPK
Clinical Trials
Review
Share
Back to top